Lamivudine Sandoz

Lamivudine, the active ingredient in Lamivudine Sandoz, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adult patients and is approved in the European Union for antiretroviral therapy.

GNH USA supplies Lamivudine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, following stringent quality standards and providing reliable global logistics.

Lamivudine is an antiretroviral nucleoside analog used in the management of viral infections that affect the immune system and liver. - HIV infection: reduces viral replication and improves immune function when used as part of combination antiretroviral therapy. - Chronic hepatitis B infection: suppresses viral DNA synthesis, leading to decreased liver inflammation and disease progression. - HIV‑1 infection in treatment‑experienced patients: provides an additional active agent to overcome resistance when combined with other antiretrovirals.

Lamivudine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Insomnia - Rash

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Pancreatitis - Severe skin reactions such as Stevens‑Johnson syndrome - Hematologic abnormalities including anemia or neutropenia - Mitochondrial toxicity leading to myopathy

When prescribing Lamivudine, clinicians should consider several safety and handling precautions. - Renal function: assess kidney performance before initiation and adjust dosing if necessary. - Hepatic disease: monitor liver enzymes regularly in patients with pre‑existing liver impairment. - Pregnancy: evaluate risk‑benefit ratio, as safety data are limited. - Concomitant antiretrovirals: review for potential additive toxicities. - Adherence: emphasize consistent daily intake to maintain viral suppression. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lamivudine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis and mitochondrial toxicity. - Stavudine: co‑administration may exacerbate peripheral neuropathy and lactic acidosis.

Moderate Interactions (Monitor Closely): - Tenofovir: may increase renal toxicity; monitor kidney function. - Efavirenz: potential for reduced lamivudine plasma levels; assess viral load. - Ribavirin: additive hematologic suppression; check blood counts. - Non‑nucleoside reverse transcriptase inhibitors (NNRTIs): may require dose adjustments based on pharmacokinetic interactions.